YS Biopharma Co., Ltd. (NASDAQ:YS - Free Report) - Research analysts at Diamond Equity lowered their FY2024 earnings per share estimates for YS Biopharma in a research note issued to investors on Monday, April 22nd. Diamond Equity analyst H. Diamond now expects that the company will post earnings per share of ($0.45) for the year, down from their previous estimate of ($0.24). The consensus estimate for YS Biopharma's current full-year earnings is ($0.24) per share. Diamond Equity also issued estimates for YS Biopharma's Q4 2024 earnings at ($0.08) EPS, Q1 2025 earnings at ($0.09) EPS, Q2 2025 earnings at ($0.08) EPS, Q3 2025 earnings at ($0.06) EPS, Q4 2025 earnings at ($0.02) EPS and FY2025 earnings at ($0.25) EPS.
YS Biopharma (NASDAQ:YS - Get Free Report) last released its earnings results on Monday, January 22nd. The company reported ($0.16) earnings per share (EPS) for the quarter. The company had revenue of $13.64 million for the quarter.
YS Biopharma Stock Performance
Shares of YS stock traded down $0.02 on Thursday, reaching $0.80. 69,379 shares of the stock were exchanged, compared to its average volume of 196,863. The firm has a 50 day moving average of $0.66 and a two-hundred day moving average of $0.57. YS Biopharma has a 1-year low of $0.35 and a 1-year high of $1.97. The company has a current ratio of 1.41, a quick ratio of 1.09 and a debt-to-equity ratio of 0.65.
Institutional Investors Weigh In On YS Biopharma
A hedge fund recently bought a new stake in YS Biopharma stock. Superstring Capital Management LP purchased a new stake in YS Biopharma Co., Ltd. (NASDAQ:YS - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 307,920 shares of the company's stock, valued at approximately $166,000. Superstring Capital Management LP owned about 0.33% of YS Biopharma as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 52.64% of the company's stock.
About YS Biopharma
(
Get Free Report)
YS Biopharma Co, Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001.
See Also
Before you consider YS Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and YS Biopharma wasn't on the list.
While YS Biopharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
